Mr. Lance R. Hummel
President
Higley Industries, Inc.
2330 Industrial Parkway SW
Dyersville , IA 52040-8748
United StatesFEI 3002984417Issued Feb 22, 2024Division of Pharmaceutical Quality Operations III
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3002984417.
Violations4
Issue DateFeb 22, 2024
Product TypeDrugs
StatusOpen
Letter Details
Firm
Higley Industries, Inc.
Location
Mr. Lance R. Hummel
President
Higley Industries, Inc.
2330 Industrial Parkway SW
Dyersville , IA 52040-8748
United States
FEI Number
3002984417
Country
United States
Issue Date
February 22, 2024
Issuing Office
Division of Pharmaceutical Quality Operations III
Product Type
Drugs
Status
Open
Summary
Higley Industries, Inc. was cited for significant Current Good Manufacturing Practice (CGMP) violations in the manufacturing of over-the-counter drug products at its Dyersville, Iowa facility during a September 2023 inspection. The company failed to adequately test incoming components for identity, purity, strength, and quality, and did not validate the reliability of supplier test analyses at appropriate intervals, instead relying solely on suppliers' certificates of analysis. Notably, the firm failed to test incoming ethanol—used as an active ingredient—for methanol contamination, a deficiency specifically highlighted by the FDA given the serious health risks associated with methanol-contaminated ethanol products. These manufacturing control failures resulted in the company's drug products being deemed adulterated under the Federal Food, Drug, and Cosmetic Act.
Higley Industries, Inc. FDA Warning Letter, February 22, 2024